BTIG Reiterates Buy on Caris Life Sciences, Maintains $38 Price Target

Benzinga · 5d ago
BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $38 price target.